Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies

Neurology

Volumn 61, Issue 9 SUPPL. 5, 2003, Pages

  Giovannoni, Gavin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA INTERFERON ANTIBODY; BETA1A INTERFERON; INFLIXIMAB; INTERFERON ANTIBODY; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CONFERENCE PAPER; DRUG ANTIGENICITY; DRUG CHOICE; DRUG EFFICACY; DRUG MANUFACTURE; HUMAN; IMMUNOADSORPTION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0242571617     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000092379.75791.5d     Document Type: Conference Paper

References (30)

1. Chance RE, Root MA, Galloway JA. The immunogenicity of insulin preparations. Acta Endocrinol Suppl 1976;205:185-198.
2. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-462.
3. Giovannoni G, Munschauer FE III, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:465-469.
4. Schellekens H. The immunogenicity of biopharmaceuticals. Neurology 2003;61(suppl 5):000-000.
5. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277-1285.
6. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1996;47:889-894.
7. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475.
8. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241-3248.
9. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002;99:2599-2602.
10. Takayanagi H, Kim S, Matsuo K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002;416:744-749.
11. Hayashi T, Kaneda T, Toyama Y, et al. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs in IFN-beta-inhibited osteoclast formation. J Biol Chem 2002;277:27880-27886.
12. Panitch H, Goodin DS, Francis G, et al. EVIDENCE Study Group. Evidence of interferon dose-response: European North American comparative efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-1506.
13. Durelli L, Verdun E, Barbero P, et al. Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460.
14. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 1997;17(suppl 1):S15-S21.
15. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
16. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
17. Clanet M, Radue EW, Kappos L, et al, European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002;59:1507-1517.
18. Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 2003;18:865-869.
19. Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant 2002;17(suppl 5):42-47.
20. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148-153.
21. Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 1992;13:507-512.
22. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.
23. Ingerslev J. Hemophilia. Strategies for the treatment of inhibitor patients. Haematologica 2000;85(10 suppl):15-20.
24. Pozzilli C, Antonini G, Bagnato F, et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1b: a randomized trial in multiple sclerosis. J Neurol 2002;249:50-56.
25. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9:418-435.
26. Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999;5:203-206.
27. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 2000;111:78-90.
28. Kakavanos R, Turner CT, Hopwood JJ, Kakkis ED, Brooks DA. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis. I. Lancet 2003;361:1608-1613.
29. Herndon RM, Jacobs LD, Coats ME, et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care 1999;2:1-6.
30. Perini P, Facchinetti A, Bulian P, et al. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001;12:56-61.